Franklin, Massachusetts based Echo Therapeutics has announced the initiation of a clinical study testing the viability of the firm’s Symphony™ tCGM product. Last year we wrote about Echo’s success at pre-clinical trials of the system. MassDevice has reported that it cost the company about $60 million for the development of the system to get to this point.
“We are extremely pleased to take this next step forward in the development work on our one piece biosensor, a critical component of Symphony, our needle-free, continuous glucose monitoring technology,” stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. “As we described previously, this next generation biosensor introduces new materials and a more effective geometrical construction designed to be one-piece and replaces the prior prototype two-piece biosensor used in earlier clinical trials. We believe that this biosensor will demonstrate improved performance and reliability and we look forward to confirming this in this clinical trial in Type 1 and Type 2 diabetics.”
Echo’s pilot clinical study will enroll patients with diabetes (either Type 1 or Type 2) and will compare data obtained from its Symphony tCGM System with the “gold standard” YSI Glucose Analyzer. The study will collect approximately 900 data pairs to be used in the analyses. Reference glucose measurements will be made at 15 minute intervals for 24 hours with the study data blinded to study subjects and study personnel.
Press release: Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients …
Flashback: Positive Results for Echo Therapeutics’ Noninvasive Glucometer
Product page: Symphony tCGM System …
(hat tip: MassDevice)